scispace - formally typeset
J

Javier E. Girardini

Researcher at National Scientific and Technical Research Council

Publications -  23
Citations -  738

Javier E. Girardini is an academic researcher from National Scientific and Technical Research Council. The author has contributed to research in topics: Mutant & Ferredoxin. The author has an hindex of 10, co-authored 19 publications receiving 672 citations. Previous affiliations of Javier E. Girardini include Facultad de Ciencias Médicas & AREA Science Park.

Papers
More filters
Journal ArticleDOI

The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP

TL;DR: It is found that Pin1 is required for efficient loading of p53 on target promoters upon stress and is recruited to chromatin by p53 and stimulates binding of the p300 acetyltransferase and consequent p53 acetylation.
Journal ArticleDOI

Molecular detection of Histoplasma capsulatum var. capsulatum in human clinical samples

TL;DR: A seminested PCR for the diagnosis of histoplasmosis that amplifies a portion of the Histoplasma capsulatum H antigen gene is developed that is highly sensitive and specific, being able to detect genomic material corresponding to less than 10 yeast cells without cross-reaction against other bacterial or fungal pathogens.
Journal ArticleDOI

Characterization of an omega-class glutathione S-transferase from Schistosoma mansoni with glutaredoxin-like dehydroascorbate reductase and thiol transferase activities

TL;DR: It is reported here that SmGSTO protein is a 28-kDa polypeptide, detected in all life stages of the parasite, being highly expressed in adult worms, and displayed significant glutathione-dependent dehydroascorbate reductase and thiol transferase enzymatic activities.
Journal ArticleDOI

Peptide aptamers targeting mutant p53 induce apoptosis in tumor cells.

TL;DR: Transient expression of PAs was able to reduce the transactivation activity of Mutant p53 and to induce apoptosis specifically in cells expressing mutant p53, which could provide a potential strategy to inhibit the oncogenic functions of mutant p52 and improve mutant p 53-targeted cancer therapies.